Drug Approval | August 12, 2021
Biocon Biologics and Viatris receive approval for first interchangeable biosimilar Semglee
The company is eligible for 12 months exclusivity from launch
The company is eligible for 12 months exclusivity from launch
Sitagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
The TWYMEEG approval is supported by numerous preclinical and clinical studies, including the Phase 3 TIMES (Trials of IMeglimin for Efficacy and Safety) program managed jointly by both the companies
Promising drug pipeline, focus on gene therapy and innovative digital health solutions will remain the key pillars of Bayer’s pharmaceutical business
Subscribe To Our Newsletter & Stay Updated
